美罗华联合CHOP方案治疗老年弥漫大B细胞性淋巴瘤的临床研究

目的观察美罗华（利妥昔单抗，Rituximab）联合COTP方案化疗治疗方案治疗老年弥漫大B细胞性淋巴瘤的临床疗效和毒副反应。方法13例老年弥漫大B细胞淋巴瘤行RCHOP方案：美罗华375mg／m^2，静脉滴注，每1个周期第1天（d1）；环磷酰胺750mg／m^2，静脉注射，d1；表阿霉素60mg／m2，静脉注射，d1；长春新碱1．4mg／m^2，静脉注射，d1；强的松100mg，口服，d1-d5每21d为1个周期，重复治疗。全部13例患者完成6个周期化疗后进行疗效评价，随访观察生存情况。结果总有效率（CR＋PR）84．6％（11／13），1年PFS率为76．9％（10／13），1年总生存率为92．3％（12／13）。结论美罗华联合CHOP（RCHOP）方案治疗老年弥漫大B细胞淋巴瘤安全、有效。

A Study of Rituximab Combined with ECHOP Regimen for Treatment of the Elderly Patients with Diffuse Large B-Cell Lymphoma

Objective To evaluate the efficacy and toxicity of combination chemotherapy consisting of Rituximab and CHOP(R-CHOP)in elderly patients with diffuse large B-cell lymphoma. Methods 13 patients with elderly patients with diffuse large B-cell lymphoma treated with the Rituximab and CHOP(R-CHOP) regimen. R-CHOP regimen:Rituximab 375 mg/m2 was infused on the first day, Cyclophosphamide 750 mg/m2 Ⅳ,Vincristine 1.4 mg/m2 Ⅳ, and Epirubicin 60 mg/m2 Ⅳ were administered on the first day of the chemotherapy course;Prednisone 100 mg was administered orally from the first day to the fifth day;the cycle was repeated every 21 days. All of the patients have received at least 6 chemotherapy cycles. The therapeutic effect was assessed. All patients were followed up. Results Overall response rate were 84.6%, The 1-year progression free and overall survial rates were 76.9% and 92.3%. Conclusion Combination chemotherapy including Rituximab and CHOP(R-CHOP) is effective and safety in treatment for elderly patients with diffuse large B-cell lymphoma.